References
- Abuhasira R, Schleider -LB-L, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018 Mar;49:44–50. doi:https://doi.org/10.1016/j.ejim.2018.01.019.
- Han BH, Palamar JJ. Trends in cannabis use among older adults in the United States, 2015-2018. JAMA Intern Med [Internet]. 2020 Feb 24;180:609. doi:https://doi.org/10.1001/jamainternmed.2019.7517.
- Choi NG, DiNitto DM. Comparing older nonmedical and medical cannabis users: health-related characteristics, cannabis use patterns, and cannabis sources. Am J Drug Alcohol Abuse. 2021 Apr 29. 1–11. doi:https://doi.org/10.1080/00952990.2021.1908318.
- Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012 Feb;87:172–86. doi:https://doi.org/10.1016/j.mayocp.2011.10.003.
- Morean ME, Lederman IR. Prevalence and correlates of medical cannabis patients’ use of cannabis for recreational purposes. Addict Behav. 2019 Jun;93:233–39. doi:https://doi.org/10.1016/j.addbeh.2019.02.003.
- Schauer GL, King BA, Bunnell RE, Promoff G, McAfee TA. Toking, vaping, and eating for health or fun. Am J Prev Med. 2016 Jan;50:1–8. doi:https://doi.org/10.1016/j.amepre.2015.05.027.
- Wynia MK. The compassionate utilitarian: reconciling the competing moral values behind efforts to regulate cannabis use. Int J Ment Health Addiction. 2018 Aug;16:813–23. doi:https://doi.org/10.1007/s11469-018-9903-y.
- Zolotov Y, Vulfsons S, Zarhin D, Sznitman S. Medical cannabis: an oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy. 2018 Jul;57:4–10. doi:https://doi.org/10.1016/j.drugpo.2018.03.025.
- Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 2015 Aug;70:989–95. doi:https://doi.org/10.1093/gerona/glv013.
- Nutt DJ, Phillips LD, Barnes MP, Brander B, Curran HV, Fayaz A, et al. A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. Cannabis Cannabinoid Res 2021;X:1–19.
- Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ. Pills to pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain. J Pain. 2019 Jul;20:830–41. doi:https://doi.org/10.1016/j.jpain.2019.01.010.
- Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016 Jun 1;17:739–44. doi: https://doi.org/10.1016/j.jpain.2016.03.002.
- Purcell C, Davis A, Moolman N, Taylor SM. Reduction of benzodiazepine use in patients prescribed medical cannabis. Cannabis Cannabinoid Res. 2019 Sep 1;4:214–18. doi: https://doi.org/10.1089/can.2018.0020.
- Bachhuber M, Arnsten JH, Wurm G. Use of cannabis to relieve pain and promote sleep by customers at an adult use dispensary. J Psychoactive Drugs. 2019 Oct 20;51:400–04. doi: https://doi.org/10.1080/02791072.2019.1626953.
- Zendulka O, Dovrtělová G, Nosková K, Turjap M, Šulcová A, Hanuš L, Juřica J. Cannabinoids and cytochrome P450 interactions. CDM. 2016 Feb 12;17:206–26. doi:https://doi.org/10.2174/1389200217666151210142051.
- Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, Karia K, Panguluri SK. Cardiovascular risks associated with gender and aging. J Cardiovas Dev Dis. 2019 Jun; 6:19. doi:https://doi.org/10.3390/jcdd6020019.
- Singh A, Saluja S, Kumar A, Agrawal S, Thind M, Nanda S, Shirani J. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018 Jun;7:45–59. doi:https://doi.org/10.1007/s40119-017-0102-x.
- Abuhasira R, Haviv YS, Leiba M, Leiba A, Ryvo L, Novack V. Cannabis is associated with blood pressure reduction in older adults – a 24-hours ambulatory blood pressure monitoring study. Eur J Intern Med. 2021 Apr 1;86:79–85. doi:https://doi.org/10.1016/j.ejim.2021.01.005.
- Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23;313:2456. doi: https://doi.org/10.1001/jama.2015.6358.
- Lisdahl KM, Gilbart ER, Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry [Internet]. 2013;4. [accessed 2021 May 27]. http://journal.frontiersin.org/article/10.3389/fpsyt.2013.00053/abstract.
- Sagar KA, Gruber SA. Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int Rev Psychiatry. 2018 May 4;30:251–67. doi: https://doi.org/10.1080/09540261.2018.1460334.
- Sánchez AJ, García-Merino A. Neuroprotective agents: cannabinoids. Clin Immunol. 2012 Jan 1;142:57–67. doi: https://doi.org/10.1016/j.clim.2011.02.010.
- Weinstein G, Sznitman SR. The implications of late-life cannabis use on brain health: a mapping review and implications for future research. Ageing Res Rev. 2020 Feb;59:101041. doi:https://doi.org/10.1016/j.arr.2020.101041.
- Sagar KA, Dahlgren MK, Smith RT, Lambros AM, El-Abboud CE, Gruber SA. An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J Int Neuropsycholl Soc. in press.